证券代码：301363 证券简称：美好医疗 公告编号：2025-007 深圳市美好创亿医疗科技股份有限公司 关于开立募集资金专项账户 并签订募集资金四方监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可〔2022〕1441 号）、深圳证券交易 所《关于深圳市美好创亿医疗科技股份有限公司人民币普通股股票在创业板上市 的通知》（深证上〔2022〕986 号）同意，深圳市美好创亿医疗科技股份有限公 司（以下简称"公司"）首次公开发行人民币普通股（A 股）股票 4,427 万股， 发行价格为 30.66 元/股，募集资金总额 1,357,318,200.00 元，扣除发行费用人民 币 132,529,143.83 元后，募集资金净额为 1,224,789,056.17 元。天健会计师事务 所（特殊普通合伙）已对公司首次公开发行股票的资金到位情况进行了审验，并 于 2022 年 9 月 30 日出具了《验资报告》（天健验〔202 ...

Company Overview - Meihao Medical closed at 22.73 yuan, down 19.25%, with a rolling PE ratio of 34.10 times and a total market value of 9.243 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 43.33 times and a median of 27.80 times, placing Meihao Medical at the 79th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Meihao Medical was 9,334, an increase of 687 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The main products include home ventilator components, cochlear implant components, other medical product components, precision molds, automation equipment, and components for home and consumer electronics [1] - The company has been recognized multiple times as a "Best Supplier" by Client A and awarded "Most Valuable Service and Excellent Partner" by Client B for five consecutive years [1] Financial Performance - In the latest quarterly report for Q3 2024, Meihao Medical achieved a revenue of 1.157 billion yuan, representing a year-on-year increase of 10.86% [1] - The net profit for the same period was 258 million yuan, showing a year-on-year decrease of 14.07% [1] - The sales gross margin stood at 41.78% [1]

4月1日，美好医疗今日收盘29.8元，上涨2.05%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到44.70倍，创27天以来新低，总市值121.18亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)84美好医疗44.7038.683.58121.18亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11328.30亿10中红医疗-54.40-37.010.8648.44 亿11天智航-46.58-46.584.8657.34亿 来源：金融界 ...

最新一期业绩显示，2024年三季报，公司实现营业收入11.57亿元，同比10.86%；净利润2.58亿元，同 比-14.07%，销售毛利率41.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)83美好医疗43.1737.363.45117.04亿行业平均 45.2249.254.85107.95亿行业中值32.5731.042.4948.28亿1硕世生物-1928.41-1928.411.2139.84亿2诺唯 赞-570.10-570.102.4696.93亿3博晖创新-299.11-184.163.3045.91亿4康泰医学-292.1334.272.9856.81亿5华 大基因-217.12237.502.25220.63亿6奥精医疗-119.63-119.631.5221.67亿7睿昂基因-82.87-82.871.2911.99亿 8华大智造-55.62-55.624.17333.25亿9中红医疗-54.23-36.890.8648.28亿10热景生物-49.79-49.792.7489.25亿 11天智航-46.17-46.174.8256.85亿 资金流向方面，3月28日，美好医 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025- 006 深圳市美好创亿医疗科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于 2024 年 3 月 27 日召开第二届董事会第九次会议，审议通过了《关于回购公司股份方案的 议案》。同意公司使用不低于人民币 5,000 万元（含），不超过人民币 10,000 万 元（含）的自有资金以集中竞价交易方式回购公司已发行的部分人民币普通股 A 股股份，回购的股份将全部用于实施股权激励计划或员工持股计划，回购期限自 公司董事会审议通过回购方案之日起 12 个月内。具体内容详见公司分别于 2024 年 3 月 28 日、2024 年 4 月 4 日在巨潮资讯网（www.cninfo.com.cn）披露的《关 于回购公司股份方案的公告》（公告编号：2024-011）和《回购报告书》（公告 编号：2024-013）。 截至 2025 年 3 月 27 日，公司本次股份回购期限已届满，回购方案已实施完 毕。根据《上市公司股份回购规则》《深圳证券 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-006 深圳市美好创亿医疗科技股份有限公司 关于回购公司股份期限届满暨回购完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于 2024 年 3 月 27 日召开第二届董事会第九次会议，审议通过了《关于回购公司股份方案的 议案》。同意公司使用不低于人民币 5,000 万元（含），不超过人民币 10,000 万 元（含）的自有资金以集中竞价交易方式回购公司已发行的部分人民币普通股 A 股股份，回购的股份将全部用于实施股权激励计划或员工持股计划，回购期限自 公司董事会审议通过回购方案之日起 12 个月内。具体内容详见公司分别于 2024 年 3 月 28 日、2024 年 4 月 4 日在巨潮资讯网（www.cninfo.com.cn）披露的《关 于回购公司股份方案的公告》（公告编号：2024-011）和《回购报告书》（公告 编号：2024-013）。 截至 2025 年 3 月 27 日，公司本次股份回购期限已届满，回购方案已实施完 毕 ...

Group 1 - The core viewpoint of the article highlights the performance of Meihao Medical, which closed at 28.87 yuan, up 1.55%, with a rolling PE ratio of 43.31 times, marking a new low in 11 days, and a total market capitalization of 11.74 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device sector is 44.91 times, with a median of 31.89 times, placing Meihao Medical at the 84th position in the industry ranking [1] - As of March 10, 2025, the number of shareholders for Meihao Medical increased to 8,647, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components and cochlear implant components [1] - The latest financial results for the third quarter of 2024 show that the company achieved a revenue of 1.157 billion yuan, a year-on-year increase of 10.86%, while net profit was 258 million yuan, reflecting a year-on-year decrease of 14.07%, with a gross profit margin of 41.78% [1]

证券代码：301363 证券简称：美好医疗 公告编号：2025-005 深圳市美好创亿医疗科技股份有限公司 关于开立募集资金专项账户 并签订募集资金四方监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 1 行手续费的净额等，具体金额以实际结转时募集资金账户余额为准）用于实施新 项目"境外医疗器械生产销售平台项目"，差额部分公司将以自有资金或自筹资金 补足。同时，公司董事会授权公司管理层全权办理与本次募集资金专项账户相关 的事宜，包括但不限于确定及签署本次设立募集资金专项账户的相关协议及文件、 签订募集资金监管协议等。具体内容详见公司于 2024 年 11 月 21 日在巨潮资讯 网（www.cninfo.com.cn）披露的《关于变更部分募集资金用途的公告》（公告编 号：2024-057）。 鉴于本次募集资金投资项目由公司全资子公司米曼（马来西亚）有限公司实 施，为规范公司募集资金的管理和使用，充分保护中小投资者的权益，根据《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律法 ...

关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301363 证券简称：美好医疗 公告编号：2025-004 深圳市美好创亿医疗科技股份有限公司 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于 2024 年 3 月 27 日召开第二届董事会第九次会议，审议通过了《关于回购公司股份方案的 议案》。同意公司使用不低于人民币 5,000 万元（含），不超过人民币 10,000 万 元（含）的自有资金以集中竞价交易方式回购公司已发行的部分人民币普通股 A 股股份，回购的股份将全部用于实施股权激励计划或员工持股计划，回购期限自 公司董事会审议通过回购方案之日起 12 个月内。具体内容详见公司分别于 2024 年 3 月 28 日、2024 年 4 月 4 日在巨潮资讯网（www.cninfo.com.cn）披露的《关 于回购公司股份方案的公告》（公告编号：2024-011）和《回购报告书》（公告 编号：2024-013）。 现将公司回购进展情况公告如下： （2）中国证监会、深圳证券交易所规定的其他情形。 一、回购进展情况 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, focusing on innovation, overseas expansion, thematic investments, and dividend strategies as the main investment themes [2][17]. Core Insights - The pharmaceutical sector experienced a short-term pullback but remains optimistic about the innovation-driven growth trajectory. Key areas of focus include innovative drugs, international market expansion, and supportive policies for innovation [2][17]. - The report highlights the importance of innovative drugs as a new productive force, with significant policy support expected to accelerate their development [17]. - The report emphasizes the potential of companies with strong clinical pipelines and innovative capabilities, particularly in the context of recent supportive policies for innovative drugs [16][17]. Summary by Sections Current Industry Investment Strategy - The pharmaceutical index fell by 2.72% in the week, underperforming the CSI 300 index by 1.97 percentage points. Year-to-date, the sector has risen by 1.11%, outperforming the CSI 300 by 1.75 percentage points [15]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 26.53 times, with a premium of 75.91% relative to the entire A-share market [15]. Key Companies and Their Performance - **Hengrui Medicine**: Recent updates on lung cancer data show promising results, with an overall response rate (ORR) of 73% and median progression-free survival (mPFS) of 11.5 months, indicating strong commercial potential [16]. - **Innovative Drug Policies**: New policies are expected to encourage commercial insurance companies to invest in innovative drug companies and improve pricing standards [16][17]. Thematic Investment Lines - **Innovation and Overseas Expansion**: The report identifies innovative drugs as a key area, with a high success rate in recent insurance negotiations for innovative drugs [17]. - **Dividend Strategy**: With the 10-year government bond yield falling below 2%, dividend-paying assets with stable growth and cash flow are highlighted as defensive and offensive investment options [9][18]. Recommended Investment Combinations - The report lists several recommended stocks, including Hengrui Medicine, Enhua Pharmaceutical, and Yifan Pharmaceutical, among others, indicating a strong buy rating for these companies based on their growth potential and market performance [19][22].